Skip to search formSkip to main contentSkip to account menu
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
TLDR
The addition of bevacizumab to fluorouracil-based combination chemotherapy results in statistically significant and clinically meaningful improvement in survival among patients with metastatic colorectal cancer.
View on PubMed
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
View on Elsevier
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.
TLDR
Bvacizumab in combination with carboplatin and paclitaxel improved overall response and time to progression in patients with advanced or recurrent non-small-cell lung cancer.
View on PubMed
First‐Line Atezolizumab plus Chemotherapy in Extensive‐Stage Small‐Cell Lung Cancer
TLDR
The addition of atezolizumab to chemotherapy in the first‐line treatment of extensive‐stage small‐cell lung cancer resulted in significantly longer overall survival and progression‐free survival than chemotherapy alone.
View on Wolters Kluwer
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.
TLDR
The encouraging results of this randomized trial support further study of bevacizumab 5 mg/kg plus chemotherapy as first-line therapy for metastatic colorectal cancer.
View on PubMed
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.
TLDR
Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first- line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival.
View on PubMed
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
TLDR
Combination treatment with bevacizumab and chemotherapy, compared with chemotherapy alone, was associated with an increased risk of arterial thromboembolism but not venous thrombosis, and Baseline or on-study aspirin use wasassociated with modest increases in grade 3 and 4 bleeding events.
View on PubMed
Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.
TLDR
The FU/LV/BV regimen seems as effective as IFL and has an acceptable safety profile, and is an active alternative treatment regimen for patients with previously untreated metastatic CRC.
View on PubMed
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.
View on PubMed
Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer.
TLDR
Men with nonmetastatic prostate cancer and rising PSA despite androgen deprivation therapy have a relatively indolent natural history and baseline PSA and PSA velocity independently predict time to first bone metastasis and survival.
View on PubMed
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License